Showing 81 - 100 results of 301 for search '"Food and Drug Administration"', query time: 0.04s Refine Results
  1. 81
  2. 82

    Andexanet alfa: trials just leave us with more questions by Richard J. Buka

    Published 2025-01-01
    “…The trial, which randomized patients with intracranial hemorrhage to andexanet alfa or usual care, was mandated by the United States Food and Drug Administration as part of its conditional approval in 2018. …”
    Get full text
    Article
  3. 83

    Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy by A. Aartsma-Rus

    Published 2025-01-01
    “…This review discusses how HDAC inhibition addresses DMD pathophysiology in a multi-targeted mode of action and summarizes the recent evidence on the rationale for HDAC inhibition with givinostat, which is now approved by the United States Food and Drug Administration for the treatment of DMD in patients aged 6 years and older.…”
    Get full text
    Article
  4. 84

    New Onset Tinnitus after High-Frequency Spinal Cord Stimulator Implantation by Alexander V. Golovlev, Michael G. Hillegass

    Published 2019-01-01
    “…To further explore these less common neurologic complications of SCS therapy, a review of literature and a review of the U.S. Food and Drug Administration Manufacturer and User Facility Device Experience database are included. …”
    Get full text
    Article
  5. 85

    Fibromyalgia: do I tackle you with pharmacological treatments? by Serge Perrot

    Published 2025-02-01
    “…Globally, pharmacological approaches are weakly effective but market authorization differs between Europe and United States. Food and Drug Administration–approved medications for fibromyalgia treatment include serotonin and noradrenaline reuptake inhibitors, such as duloxetine, and pregabalin (an anticonvulsant), which target neurotransmitter modulation and central sensitization. …”
    Get full text
    Article
  6. 86

    Ipilimumab: A First-in-Class  T-Cell Potentiator for Metastatic Melanoma by Bartosz Chmielowski

    Published 2013-01-01
    “…In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. …”
    Get full text
    Article
  7. 87

    Reviews of spinal muscular atrophy in Taiwan by Yung-Hsiu Lu, Wei-Sheng Lin, Dau-Ming Niu, Ting-Rong Hsu

    Published 2024-12-01
    “…With the advancement of medicine, the Food and Drug Administration has approved three disease-modifying therapies that could now be reimbursed with limited conditions in Taiwan. …”
    Get full text
    Article
  8. 88

    Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

    Published 2023-01-01
    “…Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). …”
    Get full text
    Article
  9. 89
  10. 90

    In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Pa... by James A Karlowsky, Mel DeCorby, Daryl J Hoban, George G Zhanel

    Published 2009-01-01
    “…BACKGROUND: In 2008, ceftobiprole was approved by Health Canada for the treatment of patients with complicated skin and skin structure infections including diabetic foot infections; approval of ceftobiprole by the United States Food and Drug Administration is pending. Doripenem is currently under review by Health Canada and was approved by the United States Food and Drug Administration in 2007 for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis. …”
    Get full text
    Article
  11. 91

    Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab by Sean McCormack, Noor Tazudeen, Benjamin C. Garden

    Published 2023-01-01
    “…Only one such biologic, adalimumab, has been approved by the US Food and Drug Administration (FDA) for the treatment of HS. Other such biologics currently being studied for HS downregulate Th1/Th17 inflammatory pathways. …”
    Get full text
    Article
  12. 92

    Neurological Crisis Following Intravenous Ozone Therapy; a Case Report by Chloe Y Y Wong, Komal Saxena, John Meneer, Koshy George, Gerben Keijzers

    Published 2025-01-01
    “…Despite claims of therapeutic benefits, Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), warn against its use due to its toxic properties and lack of proven benefits at tolerable exposure levels. …”
    Get full text
    Article
  13. 93

    Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist by So Yeong Jeong, Chong Hyun Suh, Jae-Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae-Hong Lee

    Published 2025-01-01
    “…Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea. …”
    Get full text
    Article
  14. 94

    Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms by Fengyuan Li, Kangmin Duan, Cuiling Wang, Craig McClain, Wenke Feng

    Published 2016-01-01
    “…Although many agents and approaches have been tested in patients with ALD and in animals with experimental ALD in the past, there is still no FDA (Food and Drug Administration) approved therapy for any stage of ALD. …”
    Get full text
    Article
  15. 95

    Biomarkers of traumatic brain injury. Literature review by A. Šmigelskytė, M. Remenčiūtė, V. Ragaišis

    Published 2019-03-01
    “…In the year of 2018, the US Food and Drug Administration approved a combination of GFAP and UCH-L1. …”
    Get full text
    Article
  16. 96

    Clinical Biology and Potential Use of Thrombopoietin by Russell Basser

    Published 2000-01-01
    “…However, one of these agents, interleukin-11, was successfully shown to reduce the incidence of severe thrombocytopenia in patients receiving dose-intensive chemotherapy, and has now received approval from the United States Food and Drug Administration for this purpose. Initial clinical trials of thrombopoietin, the central regulator of megakaryocytopoiesis and thrombopoiesis, and its analogues showed these agents to be the most potent stimulators of thrombopoiesis and to be associated with few adverse effects. …”
    Get full text
    Article
  17. 97

    Preventing Foodborne Illness: E. coli “The Big Six” by Susanna Richardson, Renée M. Goodrich-Schneider, Keith R. Schneider

    Published 2013-10-01
    “…In addition to E. coli O157:H7, the U.S. Food and Drug Administration has identified six serogroups (or “strains”), known as the “big six,” which includes E. coli O26, O45, O103, O111, O121, and O145. …”
    Get full text
    Article
  18. 98

    Intraoperative Imaging in Ovarian Cancer: Fact or Fiction? by Lucia M.A. Crane, Marleen van Oosten, Rick G. Pleijhuis, Arash Motekallemi, Sean C. Dowdy, William A. Cliby, Ate G.J. van der Zee, Gooitzen M. van Dam

    Published 2011-07-01
    “…These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. …”
    Get full text
    Article
  19. 99
  20. 100

    Preventing Foodborne Illness: E. coli “The Big Six” by Susanna Richardson, Renée M. Goodrich-Schneider, Keith R. Schneider

    Published 2013-10-01
    “…In addition to E. coli O157:H7, the U.S. Food and Drug Administration has identified six serogroups (or “strains”), known as the “big six,” which includes E. coli O26, O45, O103, O111, O121, and O145. …”
    Get full text
    Article